Your browser doesn't support javascript.
loading
Refractory occipital neuralgia treatment with nerve decompression surgery: a case series.
Austen, William G; Remy, Katya; Packowski, Kathryn; Hazewinkel, Merel H; Gfrerer, Lisa; Mathew, Paul G.
Afiliação
  • Austen WG; Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.
  • Remy K; Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.
  • Packowski K; Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.
  • Hazewinkel MH; Division of Plastic and Reconstructive Surgery, Weill Cornell Medicine, New York, NY, United States.
  • Gfrerer L; Division of Plastic and Reconstructive Surgery, Weill Cornell Medicine, New York, NY, United States.
  • Mathew PG; Department of Neurology, Mass General Brigham Health, Foxborough, MA, United States.
Front Neurol ; 14: 1284101, 2023.
Article em En | MEDLINE | ID: mdl-38090265
ABSTRACT

Background:

The management of refractory occipital neuralgia (ON) can be challenging. Selection criteria for occipital nerve decompression surgery are not well defined in terms of clinical features and best preoperative medical management.

Methods:

In total, 15 patients diagnosed with ON by a board-certified, fellowship-trained headache specialist and referred to a plastic surgeon for nerve decompression surgery were prospectively enrolled. All subjects received trials of occipital nerve blocks (NB), at least three preventive medications, and onabotulinum toxin (BTX) prior to surgery before referral to a plastic surgeon. Treatment outcomes included headache frequency (headache days/month), intensity (0-10), duration (h), and response to medication/injectable therapies at 12 months postoperatively.

Results:

Preoperatively, median headache days/month was 30 (20-30), intensity 8 (8-10), and duration 24 h (12-24). Patients trialed 10 (±5.8) NB and 11.7 (±9) BTX cycles. Postoperatively, headache frequency was 5 (0-16) days/month (p < 0.01), intensity was 4 (0-6) (p < 0.01), and duration was 10 (0-24) h (p < 0.01). Median patient-reported percent resolution of ON headaches was 80% (70-85%). All patients reported improvement of comorbid headache disorders, most commonly migraine, and a reduction, discontinuation, or increased effectiveness of medications, NB and BTX.

Conclusion:

All patients who underwent treatment for refractory ON by a headache specialist and plastic surgeon benefited from nerve decompression surgery in various degrees. The collaborative selection criteria employed in this study may be replicable in clinical practice.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Neurol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Neurol Ano de publicação: 2023 Tipo de documento: Article